Rachel McMinn, Founder & CEO
About Neurogene
At Neurogene, our focus is to develop life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases.
OUR VISION
Push the boundaries of genetic medicine to address complex and devastating neurological diseases.
OUR MISSION
Turn devastating neurological diseases into treatable conditions, to improve the lives of patients and families impacted by these rare diseases.
OUR CULTURE
Build a corporate culture that nurtures innovation, creative problem solving, and a strong sense of purpose, while honoring the patient/caregiver mindset.
Our Core Values
IT’S BETTER TOGETHER
We address the incredible complexity of gene therapy as a team, gathering insights, ideas, and perspectives from our internal and external subject matter experts and stakeholders.
KEEP AN OPEN MIND
In the rapidly evolving field of gene therapy, we regularly ask ourselves what we can do differently to solve emerging challenges.
PATIENTS AND FAMILIES ARE WAITING
Knowing that families urgently await treatment options, we work with a sense of urgency balanced with the necessary scientific rigor to advance our gene therapy programs.
REIMAGINE THE FUTURE
We prize innovation, encourage new ideas, and actualize our vision to drive transformation in genetic medicine.
Our Leadership Team
Neurogene’s senior leadership team brings a strong sense of purpose and extensive drug development experience to the task. Our founding leaders include:
- Rachel McMinn, Ph.D.Founder and Chief Executive Officer
- Christine Mikail, J.D.President and Chief Financial Officer
- Stuart Cobb, Ph.D.Chief Scientific Officer
- Julie Jordan, M.D.Chief Medical Officer
- Effie Albanis, M.D.Senior Vice President, Early Clinical and Translational Research
- Andrew Mulberg M.D.Senior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control
- Ricardo JimenezSenior Vice President, Technical Operations
- Arvind SreedharanSenior Vice President, Business Operations